Unknown

Dataset Information

0

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.

ABSTRACT:

SUBMITTER: Gavila J 

PROVIDER: S-EPMC6325829 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.

Gavilá Joaquín J   Oliveira Mafalda M   Pascual Tomás T   Perez-Garcia Jose J   Gonzàlez Xavier X   Canes Jordi J   Paré Laia L   Calvo Isabel I   Ciruelos Eva E   Muñoz Montserrat M   Virizuela Juan A JA   Ruiz Isabel I   Andrés Raquel R   Perelló Antonia A   Martínez Jerónimo J   Morales Serafín S   Marín-Aguilera Mercedes M   Martínez Débora D   Quero Juan C JC   Llombart-Cussac Antonio A   Prat Aleix A  

BMC medicine 20190109 1

Similar Datasets

Unknown Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
| S-EPMC10107275 | biostudies-literature
Transcriptomics Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2-positive breast cancer in the adaptively randomized I-SPY2 trial.
2021-08-24 | GSE181574 | GEO
Unknown Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial.
| S-EPMC8571284 | biostudies-literature
Unknown A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.
| S-EPMC9091255 | biostudies-literature
Unknown A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
| S-EPMC6720931 | biostudies-literature
Unknown Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
| S-EPMC4433508 | biostudies-literature
Unknown Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
| S-EPMC5330708 | biostudies-literature
Unknown Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial.
| S-EPMC7760511 | biostudies-literature
Unknown Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
| S-EPMC5299741 | biostudies-literature
Unknown Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer.
| S-EPMC7876584 | biostudies-literature